logo
  

Lyra Therapeutics Names Jason Cavalier As CFO - Quick Facts

Therapeutics company Lyra Therapeutics, Inc. (LYRA) announced Monday the appointment of Jason Cavalier as Chief Financial Officer, effective today. He succeeds Don Elsey, who is retiring as the Company's CFO and is expected to serve in an advisory role to assist with the transition.

Cavalier is a highly experienced investment banker with extensive background in originating and executing financial transactions, particularly mergers and acquisitions. He will lead the Company's financial and capital markets strategy, advise on business development and transactional activities, as well as support investor and public relations.

Cavalier joins Lyra after serving as Managing Director, Head of Life Sciences Mergers & Acquisitions at Cantor Fitzgerald, where he led transactions across the medical technology, diagnostics and biopharma sectors.

Prior to Cantor, he held several senior-level positions at RBC Capital Markets, including Director, Mergers and Acquisitions. He also held investment banking roles of increasing responsibility at Barclays Capital, Bear Stearns, and Lehman Brothers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Delta Air Lines said it sees weather-related flight cancelations as AT&T and Verizon readies for 5G roll out in and around the vicinity of major U.S. airports. Most of the other airlines also confirmed the same as the implementation of the new C-Band 5G service is expected to interfere with the working of onboard aircraft instruments. Financial services firm Morgan Stanley (MS) reported Wednesday a profit for the fourth quarter that increased 10 percent from last year, reflecting 7 percent revenue growth amidst strength in Wealth Management and Investment Management business segments. Bank of America Corp. (BAC) reported Thursday that net income applicable to common shareholders for the fourth quarter grew 30 percent to $6.77 billion from last year's $5.21 billion, with earnings per share increasing to $0.82 from $0.59 in the prior year, reflecting strong operating leverage as revenues...
Follow RTT